fbpx

Atara Biotherapeutics

Pioneering Off the Shelf, Allogeneic T‑Cell Immunotherapies

At Atara, our mission is to transform the lives of patients with serious diseases through pioneering science, teamwork and a commitment to excellence. We aim to offer hope to people whose lives have been impacted by cancer and autoimmune diseases.

Atara Biotherapeutics, Inc. is a leading allogeneic T-cell immunotherapy company pioneering the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases.

Leveraging our novel allogeneic EBV T-cell platform, Atara intends to deliver treatments to patients with high unmet medical need.

Our platform aims to leverage the unique biology of EBV T cells to channel the power of the immune system and has the potential to treat a wide range of diseases.

Atara is applying this one platform to create a robust pipeline with the goal of developing treatments that improve the quality and longevity of patients' lives.

Key Features of Atara’s EBV T-Cell Platform

EBV T cells

EBV T cells naturally possess the following key characteristics:

  • Trafficking to the site of the disease
  • Specificity for disease targets with a low likelihood to harm normal cells
  • Ability to persist in the body long enough to fight disease

Allogeneic Donor Cells

Cells from donors are manufactured and stored in inventory with the goal of being readily available for patients with serious diseases

Next-Generation CAR T Technologies

Next-generation technologies designed to:

  • Improve persistence
  • Decrease cell exhaustion and death
  • Overcome the hostile tumor microenvironment
  • Target solid tumors

T-Cell Manufacturing and Delivery Platform

  • Robust, scalable manufacturing process
  • World-class facility
  • Designed for rapid delivery to patients within 3 days
  • Biologics-like cost-of-goods profile

Robust Allogeneic T-Cell Immunotherapy Pipeline

Three Strategic Priorities

Tabelecleucel (Tab-cel®) for EBV-driven diseases
ATA188 for progressive forms of multiple sclerosis (MS)
Next-generation CAR T for blood cancers and solid tumors
View Pipeline
Doug
“I learned how to cultivate wonder about life’s simple moments because I didn’t know how many moments I had left.” - Doug
Ayden
“Don’t give up. That’s the main thing.” - Ayden
Jessica
“I have always been very aware of the preciousness of life and that it is something we cannot take for granted.” - Jessica
Ola
“I am who I am because of my disability. People read my story and say, ‘You are a role model to me.’ Hearing that from others is what drives me forward.” - Ola
View Patient Stories

World-Class T-Cell Manufacturing

World-Class T-Cell Manufacturing1 World-Class T-Cell Manufacturing2 World-Class T-Cell Manufacturing3
Atara has a dedicated, expandable manufacturing facility with the flexibility to produce multiple T-cell and CAR T immunotherapies. It is designed to meet global regulatory standards and rapidly deliver products to patients from inventory within three days, with commercial validation activities near completion.
View Manufacturing

Latest News

June 07, 2021

Atara Biotherapeutics Presents Positive Tab‑cel® Long‑Term Overall Survival Data for Epstein‑Barr Virus‑Driven Post‑Transplant Lymphoproliferative Disease After Solid Organ Transplant at ATC 2021 Virtual Connect

View Press Release View All Press Releases
June 04, 2021

Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

View Press Release
May 14, 2021

Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

View Press Release
View Investor Information View Investor Presentations